Revision of bluebird bio

{{DISPLAYTITLE:Bluebird bio}}
bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer.The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency.<small> from [https://en.wikipedia.org/wiki/Bluebird_bio Wikipedia]</small>
{|
|+ 
|-
! Icon !! Service !! Username !!
{{Twt|bluebirdbio}}
{{Wb|https://www.bluebirdbio.com/|https:www.bluebirdbio.com}}
{{Ins|bluebird_bio}}
|}
{{DISPLAYTITLE:bluebird bio}}
bluebird bio, Inc., based in Cambridge, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders and cancer.The company's only - in the European Union (EU) - approved drug is betibeglogene autotemcel (Zynteglo), which treats transfusion-dependent beta thalassemia (TDT), a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy.<small> from [https://en.wikipedia.org/wiki/Bluebird_bio Wikipedia]</small>

[[VHID]]:[https://verifiedhandles.com/vhid/56205826167 56205826167]
{{#subtitle: <big>American pharmaceutical company</big>}}
{{SF|
}}
{{IDF|
{{Wd|Q85747906}}
}}

{{VHID|56205826167}}{{#subtitle: <big>company in Cambridge, United States</big>}}